Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hani A. Nabi, M.D., Ph.D. Department of Nuclear Medicine School of Medicine and Biomedical Science University at Buffalo State University of New York Buffalo,

Similar presentations


Presentation on theme: "Hani A. Nabi, M.D., Ph.D. Department of Nuclear Medicine School of Medicine and Biomedical Science University at Buffalo State University of New York Buffalo,"— Presentation transcript:

1 Hani A. Nabi, M.D., Ph.D. Department of Nuclear Medicine School of Medicine and Biomedical Science University at Buffalo State University of New York Buffalo, N.Y. USA

2 Definition: Parenchymal lesions, well defined less than 4 cm. Benign Features: Central, concentric or stippled calcifications, stable for more than 2 years, patients younger than 35 years.

3 An SUV of less than 3.5 SUV: Mean Counts/pixel/sec x calibration factor Injected dose (mCi)/body weight (kg).

4 Author Patient SizeSens.Spec. (cm) Dewan, Gupta, Patz, MultiCenter

5 SUV Tumor to background ratios SUV versus visual interpretation SUV: prognostic significance

6

7 Hypothesis FDG uptake, normalized to body weight, overestimates value in heavy patients.

8

9 Mean SUV bw and bsa same = 3.42 SD of SUV bsa smaller Mean SUV bw varies widely with bw, tending to overestimate low to intermediate FDG uptake in heavy patients and underestimate intermediate--higher FDG uptake in light patients

10 107 patients with single pulmonary nodule; 67 malignancies and 27 benign. SUV bw were compared to visual interpretation by two independent readers. FDG uptake grade 1-5 (definitely tumor) based on mediastinal uptake (=3).

11 SUV and visual analysis nearly identical. No difference between two readers. Probability of tumor high (0.93, CI ) when FDG in tumor exceeded mediastinum.

12

13 EVALUATE SUV’S AND HOW THEY ARE AFFECTED WHEN ROI’S ARE DRAWN IN DIFFERENT PLANES AND IN DIFFERENT AREAS OF THE SAME PLANE DETERMINE CLINICAL IMPORTANCE OF TUMOR/BKG RATIO OF SUV’S

14

15

16

17

18

19

20

21 SIGNIFICANT VARIATION (p 20 MINIMAL VARIATION WAS OBSERVED IN SUV’S WHEN ROI’S OF THE TUMOR WERE DRAWN ON ONE PLANE

22 UPTAKE TIME GLUCOSE LEVEL PARTIAL VOLUME EFFECT PATIENT SIZE ROI EFFECT ? NODULE SIZE?

23 JNM 2002, 43(5): 156, Coronado et al. Compared SUVs amongst nodules 3.0 cm 45 patients with SPNs SUV > mean 21 SPNs 1.5cm or less ( 2.79) 18 SPNs cm (4.88) 7 SPNs 3.0cm or greater (5.16) 32/45 FDG positive 27/30 proven neoplasia

24 Nodules 1.5cm or less (21) 04cm-1.5cm (mean 0.97cm) 11 malignant, 4 FN, 10TN FN : 1.0cm, FDG+ but SUVs less 3.5 Nodules 1.5 cm or less had lower SUV’s, a cutoff value of 2.0 might be more appropriate.

25 Journal of Hematology & Oncology :13

26 Retrospective Study (2 centers) Criteria for enrollment: Positive CT for SPN Positive FDG PET Histopathological Biopsy 173/420 patients fulfilled above criterion

27

28

29

30

31 < 1.0cm 1.1 – 2.0 cm

32 < 1.0cm1.1 – 2.0 cm2.1 – 3.0 cm> 3.0 cm

33 Average SUV’sNodules size 2.79< 1.5 cm – 3.0 cm 5.16>3.0 cm SUV max cutoff 2.5 useful in the evaluation of nodules 1cm or greater, has minimal or no value in SPN < 1.0 cm

34 Hani A. Nabi, M.D., Ph.D L. Li, M.D., Ph.D, John Baker, Ph.D Department of Nuclear Medicine School of Medicine and Biomedical Science University at Buffalo State University of New York Buffalo, N.Y. USA

35 Prognostic significance of FDG PET negative (visual or SUV less than 2.5) SPN.

36 Retrospective review of all FDG SPN patients referred by a single pulmonary group from 2000— One hundred twenty-eight (128) patients (68 females, 60 males, mean age 63 years, 56% between years) fulfilled criteria for negative scans. Mean follow-up 29.3 months (8-52 months).

37 72 (56%) were current or former tobacco users. 8 (6.2%) occupational exposure. 14 (11%) history of cancer, other than lung.

38 59% 20% 8% 12%

39 76 patients (59%) had no visual uptake. 21 had biopsy. 6 (7.9%) were malignant. 70/76 (92%) were negative on clinical follow-up of at least 18 months.

40 31.5m 12.3m Stable Follow-up

41 52 patients (41%) had FDG uptake less than had biopsy. 23/52 (44%) malignant. 29/52 were negative for malignancy on follow-up of at least 18 months.

42 Nodule types

43 55.8% 44.2% 92% 8% Comparison of benign and malignant nodule number between FDG uptake and no FDG uptake

44 Benign and malignant SUV uptake Benign Malignant

45 The difference in proportion in malignancy between the no-FDG uptake and FDG uptake groups is statistically significant. Likelihood ratio Chi-square = P <

46 SPN with no visual FDG uptake have a relatively low likelihood of malignancy (7.9%) compared to lesions with FDG SUV less than 2.5 (44%). This study confirmed our previous work (JNM 2006, 47:173) that there is no predetermined fixed value of SUV cutoff that is accurately able to diagnose malignancy in small pulmonary nodules.


Download ppt "Hani A. Nabi, M.D., Ph.D. Department of Nuclear Medicine School of Medicine and Biomedical Science University at Buffalo State University of New York Buffalo,"

Similar presentations


Ads by Google